Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VSTM

Verastem Inc

Dec 13 • 11:25AM ET

4.47

Dollar change -0.03
Percentage change -0.67	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD AMGN MRK PFE BMY REGN VRTX INCY LUMO SRPT

| Held by: IWM VTI IWO VXF VTWO IWC VTWG RSSL UWM URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.19	Insider Own	10.94%	Shs Outstand	40.26M	Perf Week	-20.88%
Market Cap	198.94M	Forward P/E	-	EPS next Y	-2.61	Insider Trans	-0.16%	Shs Float	39.64M	Perf Month	9.02%
Income	-93.45M	PEG	-	EPS next Q	-0.79	Inst Own	49.90%	Short Float	5.06%	Perf Quarter	63.74%
Sales	10.00M	P/S	19.89	EPS this Y	22.81%	Inst Trans	186.77%	Short Ratio	2.03	Perf Half Y	28.82%
Book/sh	0.27	P/B	16.27	EPS next Y	14.65%	ROA	-61.78%	Short Interest	2.00M	Perf Year	-42.54%
Cash/sh	2.55	P/C	1.75	EPS next 5Y	1.74%	ROE	-136.87%	52W Range	2.10 - 14.22	Perf YTD	-45.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.76%	ROI	-148.66%	52W High	-68.57%	Beta	0.23
Dividend TTM	-	Quick Ratio	3.23	Sales past 5Y	-45.06%	Gross Margin	99.76%	52W Low	112.86%	ATR (14)	0.43
Dividend Ex-Date	-	Current Ratio	3.23	EPS Y/Y TTM	21.19%	Oper. Margin	-1145.05%	RSI (14)	48.83	Volatility	9.89% 10.09%
Employees	73	Debt/Eq	1.29	Sales Y/Y TTM	-	Profit Margin	-934.54%	Recom	1.00	Target Price	11.12
Option/Short	Yes / Yes	LT Debt/Eq	0.95	EPS Q/Q	20.28%	Payout	-	Rel Volume	0.56	Prev Close	4.50
Sales Surprise	16.81%	EPS Surprise	18.68%	Sales Q/Q	-	Earnings	Nov 06 AMC	Avg Volume	985.21K	Price	4.47
SMA20	-3.90%	SMA50	13.45%	SMA200	-20.99%	Trades		Volume	180,746	Change	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform

Show Previous Ratings

Nov-26-24 07:00AM	Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-06-24 05:00PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -6.98%
04:05PM	Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-01-24 12:02PM	Verastem Oncology submits NDA for ovarian cancer treatment (Pharmaceutical Technology)
Oct-31-24 04:01PM	Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
07:30AM	Loading…
07:30AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Oct-17-24 01:00AM	Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting (Business Wire) -20.12%
Oct-09-24 06:00AM	Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting (Business Wire)
Oct-07-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-10-24 04:05PM	Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference (Business Wire) +8.76%
07:30AM	Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting (Business Wire)
Sep-03-24 07:30AM	Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 (Business Wire)
Aug-08-24 06:18PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Jul-29-24 04:01PM	Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer (Business Wire) -7.43%
11:20PM	Loading…
Jul-23-24 11:20PM	Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire) -17.55%
04:05PM	Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants (Business Wire)
Jul-15-24 11:42AM	Verastem (VSTM) Begins Dosing in Solid Tumors Study in China (Zacks)
04:52AM	Verastem announces dosing of first patient in trial of KRAS G12D inhibitor (Clinical Trials Arena)
Jul-12-24 07:30AM	Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics (Business Wire) +12.75%
Jul-08-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-01-24 07:30AM	Verastem Oncology Announces Addition to Russell 3000 and Russell Microcap Indexes (Business Wire) +9.06%
Jun-19-24 07:00AM	GenFleet Receives IND Approval from China's NMPA for GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation (PR Newswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-06-24 06:45AM	7 F-Rated Stocks to Avoid at All Costs in June (InvestorPlace)
Jun-03-24 09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
May-24-24 12:28PM	Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data (Zacks) -66.17%
11:43AM	Is the Stock Market Open on Memorial Day 2024? (InvestorPlace)
11:23AM	7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split (InvestorPlace)
11:01AM	NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial (InvestorPlace)
10:45AM	Loading…
10:45AM	What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday? (Benzinga)
10:39AM	Why Is Verastem (VSTM) Stock Down 62% Today? (InvestorPlace)
08:47AM	ASCO 2024: Verastems combo therapy for pancreatic cancer hits early trial success (Pharmaceutical Technology)
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
07:00AM	Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer (Business Wire)
May-23-24 05:01PM	Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer? (Business Wire)
May-09-24 10:58PM	VSTM Stock Earnings: Verastem Beats EPS for Q1 2024 (InvestorPlace)
04:56PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
May-07-24 07:30AM	Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-18-24 04:05PM	Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer (Business Wire) -5.63%
Apr-09-24 07:00AM	GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting (PR Newswire)
Apr-04-24 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.43%
Mar-18-24 07:00AM	Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer (Business Wire)
Mar-14-24 09:54PM	VSTM Stock Earnings: Verastem Misses EPS for Q4 2023 (InvestorPlace)
04:53PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-11-24 07:30AM	Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Womens Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs (Business Wire)
Mar-05-24 05:27PM	Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
04:30PM	Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024 (Business Wire)
Feb-15-24 03:12AM	Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc (GuruFocus.com)
Feb-07-24 05:02PM	Director Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM) (GuruFocus.com)
07:15AM	3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024 (InvestorPlace)
Jan-29-24 07:00AM	Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers (Business Wire) +7.12%
Jan-22-24 08:15AM	Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy (Zacks)
Jan-18-24 04:00PM	Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) (Business Wire) -6.48% +7.51%
Jan-11-24 07:00AM	Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference (Business Wire)
Jan-05-24 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-18-23 07:00AM	Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics (Business Wire)
Dec-13-23 09:08AM	3 Off-the-Beaten-Path Stocks Poised for Substantial Growth (InvestorPlace) +10.67%
07:00AM	Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Dec-03-23 04:17PM	Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential (InvestorPlace)
Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance) -5.66%
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire) -7.85%
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire) +125.55%
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)
04:05PM	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
May-02-23 07:45AM	Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
May-01-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire) +12.65%
Apr-26-23 04:05PM	New Data from Interim Analysis of Verastem Oncologys RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting (Business Wire) +5.14%
Apr-18-23 07:05AM	Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days (Business Wire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) -6.12%
04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 07:00AM	New Verastem Oncology Initiative, Lets Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer (Business Wire)
Mar-14-23 04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Feb-02-23 07:00AM	Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire) +8.65%
Jan-30-23 12:00PM	Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.80%
Jan-24-23 05:46PM	Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock (Business Wire)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paterson Dan	President and CEO	Nov 05 '24	Sale	3.84	812	3,118	231,576	Nov 07 04:30 PM
Calkins Daniel	Chief Financial Officer	Oct 07 '24	Sale	2.86	6	17	47,461	Oct 09 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 20 '24	Sale	2.80	65	182	47,495	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '24	Sale	2.68	28	75	47,467	Sep 24 04:30 PM
Gagnon Robert E.	Director	Sep 19 '24	Sale	2.79	131	365	34,892	Sep 20 06:01 PM
Paterson Dan	President and CEO	Sep 19 '24	Sale	2.79	184	513	232,388	Sep 20 06:01 PM
Stuglik Brian M	Director	Sep 19 '24	Sale	2.79	336	937	96,109	Sep 20 06:00 PM
Gagnon Robert E.	Director	Sep 16 '24	Sale	2.80	287	804	35,023	Sep 18 04:30 PM
Stuglik Brian M	Director	Sep 16 '24	Sale	2.80	600	1,680	96,445	Sep 18 04:30 PM
Paterson Dan	President and CEO	Sep 16 '24	Sale	2.80	246	689	232,572	Sep 18 04:30 PM
Paterson Dan	President and CEO	Aug 05 '24	Sale	2.16	3,245	7,009	232,818	Aug 07 04:18 PM
Calkins Daniel	Chief Financial Officer	Jul 09 '24	Sale	2.62	7	18	47,560	Jul 11 07:00 AM
Calkins Daniel	Chief Financial Officer	Jun 24 '24	Sale	3.15	28	88	47,290	Jun 26 04:30 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '24	Sale	3.16	67	212	47,318	Jun 20 08:30 PM
Gagnon Robert E.	Director	Jun 17 '24	Sale	3.49	283	988	27,108	Jun 20 08:29 PM
Gagnon Robert E.	Director	Jun 20 '24	Sale	3.21	131	421	35,310	Jun 20 08:29 PM
Paterson Dan	President and CEO	Jun 17 '24	Sale	3.49	244	852	86,246	Jun 20 08:28 PM
Paterson Dan	President and CEO	Jun 20 '24	Sale	3.21	183	587	236,063	Jun 20 08:28 PM
Stuglik Brian M	Director	Jun 17 '24	Sale	3.49	593	2,070	89,047	Jun 20 08:27 PM
Stuglik Brian M	Director	Jun 20 '24	Sale	3.21	335	1,075	97,045	Jun 20 08:27 PM
Calkins Daniel	Chief Financial Officer	Apr 05 '24	Sale	10.87	6	65	8,535	Apr 08 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 25 '24	Sale	12.02	25	300	8,541	Mar 27 04:30 PM
Calkins Daniel	Chief Financial Officer	Mar 20 '24	Sale	11.07	55	609	8,566	Mar 21 04:31 PM
Gagnon Robert E.	Director	Mar 18 '24	Sale	10.71	283	3,031	27,521	Mar 20 05:36 PM
Gagnon Robert E.	Director	Mar 19 '24	Sale	10.38	130	1,349	27,391	Mar 20 05:36 PM
Paterson Dan	President and CEO	Mar 18 '24	Sale	10.71	244	2,613	86,672	Mar 20 05:34 PM
Paterson Dan	President and CEO	Mar 19 '24	Sale	10.38	182	1,889	86,490	Mar 20 05:34 PM
Stuglik Brian M	Director	Mar 18 '24	Sale	10.71	537	5,751	89,913	Mar 20 05:32 PM
Stuglik Brian M	Director	Mar 19 '24	Sale	10.38	273	2,834	89,640	Mar 20 05:32 PM
Gagnon Robert E.	Director	Feb 06 '24	Sale	13.70	9,204	126,095	27,804	Feb 07 04:00 PM
Gagnon Robert E.	Director	Jan 12 '24	Sale	10.95	9,204	100,784	37,008	Jan 17 04:00 PM
Calkins Daniel	Chief Financial Officer	Jan 05 '24	Sale	8.50	6	51	8,621	Jan 09 04:03 PM
Calkins Daniel	Chief Financial Officer	Dec 26 '23	Sale	8.08	25	202	8,350	Dec 28 04:04 PM
Calkins Daniel	Chief Financial Officer	Dec 20 '23	Sale	7.93	57	452	8,375	Dec 21 04:01 PM
Gagnon Robert E.	Director	Dec 18 '23	Sale	7.64	284	2,170	46,342	Dec 20 04:03 PM
Gagnon Robert E.	Director	Dec 19 '23	Sale	7.73	130	1,005	46,212	Dec 20 04:03 PM
Paterson Dan	President and CEO	Dec 18 '23	Sale	7.64	244	1,864	87,099	Dec 20 04:01 PM
Paterson Dan	President and CEO	Dec 19 '23	Sale	7.73	183	1,415	86,916	Dec 20 04:01 PM
Stuglik Brian M	Director	Dec 18 '23	Sale	7.64	487	3,721	90,724	Dec 20 04:00 PM
Stuglik Brian M	Director	Dec 19 '23	Sale	7.73	274	2,118	90,450	Dec 20 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VSTM

Verastem Inc

Upgrade your FINVIZ experience